Company: IMNN
Filing Date: 2025-05-27
Form Type: 8-K
Source: 0001641172-25-012395
Chunk: 1

Company: Imunon, Inc.
Filing Date: 2025-05-27
Form: 8-K
Item: Item 1.01
Chunk 1
---
holders in connection therewith
in the same manner as all other management proposals in such proxy statement and all management appointed proxyholders will vote their
proxies in favor of such proposals. The Company agreed to file such proxy statement within 20 days following the closing date of the
Private Placement and to use the record date that was previously set on May 13, 2025 for the stockholder meeting to seek Stockholder
Approval. If the Company does not obtain Stockholder Approval at the first meeting, the Company will call a meeting every 90 days thereafter
to seek Stockholder Approval until the earlier of the date on which Stockholder Approval is obtained or the Warrants are no longer outstanding.

A
holder of the Pre-Funded Warrants and the Warrants may not exercise any portion of such holder’s Pre-Funded Warrants or Warrants
to the extent that the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder,
9.99%) of the Company’s outstanding shares of Common Stock immediately after exercise, except that upon at least 61 days’
prior notice from the holder to the Company, the holder may increase the beneficial ownership limitation to up to 9.99% of the number
of shares of Common Stock outstanding immediately after giving effect to the exercise.

In
connection with the Private Placement, the Company entered into a registration rights agreement (the “ Registration Rights Agreement”),
dated as of May 23, 2025, with the Purchasers, pursuant to which the Company agreed to prepare and file a registration statement with
the Securities and Exchange Commission (the “ SEC”) registering the resale of the Shares and the shares of Common Stock underlying
the Pre-Funded Warrants and the Warrants no later than 15 calendar days after the date of the Registration Rights Agreement (the “ Registration
Statement”), and to use its best efforts to have the Registration Statement declared effective as promptly as practical thereafter,
and in any event no later than 45 calendar days following the date of the Registration Rights Agreement (or 75 calendar days following
the date of the Registration Rights Agreement in the event of a “full review” by the SEC).

H. C.
Wainwright & Co., LLC (“ Wainwright”) is acting as the Company’s lead placement agent, and Brookline Capital
Markets, a division of Arcadia Securities, LLC, is acting as co-placement agent, in connection with the Private Placement, pursuant